8×8, Inc. Schedules Third Quarter Fiscal 2024 Earnings Release and Conference Call
CAMPBELL, Calif.–(BUSINESS WIRE)–8×8, Inc. (NASDAQ: EGHT), a leading integrated cloud contact center and unified communications platform provider,... Read more.
Hagens Berman Files New Securities Class Action Against ChargePoint (CHPT) and its Senior Executives: New Complaint Extends Alleged Fraudulent Period From Dec. 7, 2021 – Nov. 16, 2023, Inclusive; Lead Plaintiff Filing Deadline Remains Jan. 29, 2024
SAN FRANCISCO–(BUSINESS WIRE)–Hagens Berman announces that the firm has filed a new class action lawsuit against ChargePoint Holdings, Inc. (NYSE: CHPT)... Read more.
Vescent Brings Optical Clocks to the Market with DFM
GOLDEN, Colo.–(BUSINESS WIRE)–#AtomicClocks—Vescent and the Danish National Metrology Institute (DFM) announce a highly accurate user-configurable... Read more.
Optimizing Healthcare Communications with WestFax CloudFax Toolkit
DENVER–(BUSINESS WIRE)–#WestFax–WestFax proudly unveils its latest advancement in healthcare secure cloud fax technology: the CloudFax Toolkit... Read more.
Upstart to Report Fourth Quarter and Full Year 2023 Earnings on February 13, 2024
SAN MATEO, Calif.–(BUSINESS WIRE)–Upstart Holdings, Inc. (NASDAQ: UPST), a leading artificial intelligence (AI) lending marketplace, announced today... Read more.
ExxonMobil to Release Fourth Quarter 2023 Financial Results
SPRING, Texas–(BUSINESS WIRE)–Exxon Mobil Corporation (NYSE: XOM) will release its fourth quarter 2023 financial results on Friday, February 2, 2024.... Read more.
Energy Transfer LP Announces Cash Distributions on Series E and I Preferred Units
Series C and D Preferred Units to be Redeemed as Previously Announced DALLAS–(BUSINESS WIRE)–Energy Transfer LP (“ET”) today announced the quarterly... Read more.
Core Scientific, Inc. Releases Webcast and Presentation with Updates on Chapter 11 Emergence
AUSTIN, Texas–(BUSINESS WIRE)–$CORZQ #bitcoin—Core Scientific, Inc. (OTC: CORZQ) (“Core Scientific” or “the Company”), a leader... Read more.
Eight-Year Data for Opdivo (nivolumab) Plus Yervoy (ipilimumab) Continue to Demonstrate Longest Survival Benefit vs. Sunitinib Reported in Patients with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma
Patients with previously untreated advanced or metastatic renal cell carcinoma treated with Opdivo plus Yervoy experienced a 28% reduction in the risk of death vs.... Read more.
Cushman & Wakefield to Release Fourth Quarter and Full Year 2023 Earnings on February 20
CHICAGO–(BUSINESS WIRE)–#cre–Cushman & Wakefield (NYSE: CWK) will release its fourth quarter and full year 2023 financial results after the... Read more.